DOVA News and Press, Dova Pharmaceuticals Inc. From 05/20/19

DURHAM, N.C., May 20, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the UBS Global Healthcare Conference on Monday, May 20, 2019 at 2:00 p.m. ET in New York, NY.  A li...

Dova Pharmaceuticals, Inc. (DOVA) Q1 2019 Earnings Conference Call May 7, 2019 9:00 AM ET Company Participants David Zaccardelli – President and Chief Executive Officer Mark Hahn – Chief Financial Officer Jason Hoitt – Chief Commercial Officer Conference C...

Dova Pharmaceuticals (NASDAQ: DOVA ): Q1 GAAP EPS of -$0.58 beats by $0.09 . More news on: Dova Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

First Quarter 2019 net product sales of $4.0 million from DOPTELET ® (avatrombopag)   New marketing campaign launched early in second quarter for the treatment of thrombocytopenia associated with chronic liver disease (CLD)   sNDA under review by the U.S. FDA for DOP...

DURHAM, N.C., April 30, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) will host a conference call on Tuesday, May 7, 2019 at 9:00 a.m. ET to discuss first quarter 2019 financial results and recent operational highlights. A question-and-answer session will follow Dova's ...

DURHAM, N.C., April 29, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European  Medicines Agency (EMA) adopted a positive opinion for the use of DOPTELET ® for the treatment of...

The following slide deck was published by Dova Pharmaceuticals, Inc. in conjunction with this Read more ...

DURHAM, N.C., April 02, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Jason Hoitt, Chief Commercial Officer, will present a company overview at the H.C. Wainwright Global Life Sciences Conference on Tuesday, April 9, 2019 at 9:30 a.m. BST (4:30 a.m....

Dova Pharmaceuticals ( DOVA ) is a good biotech to look into because of its ability to use Doptelet to target patients with thrombocytopenia due to many different causes. Specifically, this biotech has been successful in developing a treatment for thrombocytopenia due to chronic liver diseas...

DURHAM, N.C., March 05, 2019 (GLOBE NEWSWIRE) -- Dova Pharmaceuticals, Inc. (NASDAQ: DOVA) today announced that Dr. David Zaccardelli, President and Chief Executive Officer, will present a company overview at the Cowen and Company 39 th Annual Health Care Conference on Wednesday, March 13,...